The trading price of Prime Medicine Inc (NASDAQ:PRME) floating lower at last check on current market day and closing at $2.81, -3.10% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $2.79 and $2.885. In examining the 52-week price action we see that the stock hit a 52-week high of $9.80 and a 52-week low of $2.56. Over the past month, the stock has lost -14.85% in value.
Prime Medicine Inc, whose market valuation is $363.55 million at the time of this writing, is expected to release its quarterly earnings report in January. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest PRME has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PRME a recommendation rating is 5. Out of them, 1 rate it a Hold, while 4 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Prime Medicine Inc (PRME) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that PRME’s price is currently -6.27% off the SMA20 and -19.48% off the SMA50. The RSI metric on the 14-day chart is currently showing 41.33, and weekly volatility stands at 8.65%. When measured over the past 30 days, the indicator reaches 7.83%. Prime Medicine Inc (NASDAQ:PRME)’s beta value is currently sitting at 1.90, while the Average True Range indicator is currently displaying 0.24. With analysts defining $12-$23 as the low and high price targets, we arrive at a consensus price target of $17 for the trailing 12-month period. The current price is about -327.05% off the estimated low and -718.51% off the forecast high, based on this estimate. Investors will be thrilled if PRME’s share price rises to $17, which is the median consensus price. At that level, PRME’s share price would be -504.98% below current price.
To see how Prime Medicine Inc stock has been performing today in comparison to its peers in the industry, here are the numbers: PRME stock’s performance was -3.10% at last check in today’s session, and -70.58% in the past year.
An evaluation of the daily trading volume of Prime Medicine Inc (NASDAQ:PRME) indicates that the 3-month average is 1.78 million. However, this figure has increased over the past 10 days to an average of 1.26.
Currently, records show that 131.16 million of the company’s shares remain outstanding. The insiders hold 61.20% of outstanding shares, whereasinstitutions hold 36.06%. The stats also highlight that short interest as of 2024-12-13, stood at 16.13 million shares, resulting in a short ratio of 12.98 at that time. From this, we can conclude that short interest is 2363.00 of the company’s total outstanding shares. It is noteworthy that short shares in December were up slightly from the previous month’s figure, which was 15.19 million. However, since the stock’s price has seen -68.28% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
